BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR Jr, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019;200:e93-e142. [PMID: 31729908 DOI: 10.1164/rccm.201909-1874ST] [Cited by in Crossref: 108] [Cited by in F6Publishing: 43] [Article Influence: 54.0] [Reference Citation Analysis]
Number Citing Articles
1 Kobayashi M, Motoki Y, Yamagishi T, Hirano H, Nonaka M, Aono A, Mitarai S, Saito T. A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline. J Infect Chemother 2022:S1341-321X(22)00142-8. [PMID: 35550867 DOI: 10.1016/j.jiac.2022.04.028] [Reference Citation Analysis]
2 Alffenaar JC, Jongedijk EM, van Winkel CAJ, Sariko M, Heysell SK, Mpagama S, Touw DJ. A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva. J Antimicrob Chemother 2021;76:423-9. [PMID: 33089322 DOI: 10.1093/jac/dkaa420] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Al-Shaer MH, Märtson AG, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, Banu S, Houpt ER, Ashkin D, Griffith DE, Cegielski JP, Heysell SK, Peloquin CA. Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother 2020;64:e00713-20. [PMID: 32631828 DOI: 10.1128/AAC.00713-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Sotgiu G, Battista Migliori G, Menzies D, Mase S, Chorba T, Seaworth B, Nahid P. Reply to Chang and Yew. Am J Respir Crit Care Med 2020;202:778-9. [PMID: 32374628 DOI: 10.1164/rccm.202003-0698LE] [Reference Citation Analysis]
5 Radcliffe C, Grant M. Pott Disease: A Tale of Two Cases. Pathogens 2021;10:1158. [PMID: 34578190 DOI: 10.3390/pathogens10091158] [Reference Citation Analysis]
6 Fage D, Brilleman R, Deprez G, Payen M, Cotton F. Development, validation and clinical use of a LC-MS/MS method for the simultaneous determination of the nine main antituberculosis drugs in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2022;215:114776. [DOI: 10.1016/j.jpba.2022.114776] [Reference Citation Analysis]
7 Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLoS One 2021;16:e0254453. [PMID: 34320004 DOI: 10.1371/journal.pone.0254453] [Reference Citation Analysis]
8 Li Y, Deng Y, He J. Monocyte-related gene biomarkers for latent and active tuberculosis. Bioengineered 2021;12:10799-811. [PMID: 34751089 DOI: 10.1080/21655979.2021.2003931] [Reference Citation Analysis]
9 Malenfant JH, Brewer TF. Rifampicin Mono-Resistant Tuberculosis-A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control. Open Forum Infect Dis 2021;8:ofab018. [PMID: 33623803 DOI: 10.1093/ofid/ofab018] [Reference Citation Analysis]
10 Khongyot T, Laopaiboonkun S, Kawpradid T, Jitkamrop K, Chanphakphoom T, Uitrakul S, Suksaeree J. Levofloxacin Use in Patients with Suspected Tuberculosis in a Community Hospital, Thailand: A Pilot Study. Advances in Pharmacological and Pharmaceutical Sciences 2022;2022:1-5. [DOI: 10.1155/2022/5647071] [Reference Citation Analysis]
11 Bahlool AZ, Grant C, Cryan S, Keane J, O'sullivan MP. All trans retinoic acid as a host-directed immunotherapy for tuberculosis. Current Research in Immunology 2022;3:54-72. [DOI: 10.1016/j.crimmu.2022.03.003] [Reference Citation Analysis]
12 Parums DV. Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis. Med Sci Monit 2021;27:e934292. [PMID: 34366429 DOI: 10.12659/MSM.934292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM, Allwood B, Byrne AL, Mortimer K, Wallis RS, Fox GJ, Leung CC, Chakaya JM, Seaworth B, Rachow A, Marais BJ, Furin J, Akkerman OW, Al Yaquobi F, Amaral AFS, Borisov S, Caminero JA, Carvalho ACC, Chesov D, Codecasa LR, Teixeira RC, Dalcolmo MP, Datta S, Dinh-Xuan AT, Duarte R, Evans CA, García-García JM, Günther G, Hoddinott G, Huddart S, Ivanova O, Laniado-Laborín R, Manga S, Manika K, Mariandyshev A, Mello FCQ, Mpagama SG, Muñoz-Torrico M, Nahid P, Ong CWM, Palmero DJ, Piubello A, Pontali E, Silva DR, Singla R, Spanevello A, Tiberi S, Udwadia ZF, Vitacca M, Centis R, D Ambrosio L, Sotgiu G, Lange C, Visca D. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis 2021;25:797-813. [PMID: 34615577 DOI: 10.5588/ijtld.21.0425] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Riccardi N, Canetti D, Rodari P, Besozzi G, Saderi L, Dettori M, Codecasa LR, Sotgiu G. Tuberculosis and pharmacological interactions: A narrative review. Curr Res Pharmacol Drug Discov 2021;2:100007. [PMID: 34909643 DOI: 10.1016/j.crphar.2020.100007] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kamada K, Mitarai S. Anti-Mycobacterial Drug Resistance in Japan: How to Approach This Problem? Antibiotics (Basel) 2021;11:19. [PMID: 35052896 DOI: 10.3390/antibiotics11010019] [Reference Citation Analysis]
16 Chang KC, Yew WW. ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword? Am J Respir Crit Care Med 2020;202:777-8. [PMID: 32374633 DOI: 10.1164/rccm.201912-2460LE] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sulis G, Pai M. Isoniazid-resistant tuberculosis: A problem we can no longer ignore. PLoS Med 2020;17:e1003023. [PMID: 31961857 DOI: 10.1371/journal.pmed.1003023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
18 Clough I. Clinical News. Br J Hosp Med (Lond) 2019;80:692-5. [PMID: 31822174 DOI: 10.12968/hmed.2019.80.12.692] [Reference Citation Analysis]
19 McDowell A, Haas M, Seaworth B, Wilson JW, Patrawalla A, Haley C, Lauzardo M, de Bruyn M, Goswami ND. Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013-2018. J Clin Tuberc Other Mycobact Dis 2021;22:100201. [PMID: 33336084 DOI: 10.1016/j.jctube.2020.100201] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Chen S, Rong X, Sun X, Zou Y, Zhao C, Wang H. A Novel Trimethylamine Oxide-Induced Model Implicates Gut Microbiota-Related Mechanisms in Frailty. Front Cell Infect Microbiol 2022;12:803082. [DOI: 10.3389/fcimb.2022.803082] [Reference Citation Analysis]
21 Vogel M, Utpatel C, Corbett C, Kohl TA, Iskakova A, Ahmedov S, Antonenka U, Dreyer V, Ibrahimova A, Kamarli C, Kosimova D, Mohr V, Sahalchyk E, Sydykova M, Umetalieva N, Kadyrov A, Kalmambetova G, Niemann S, Hoffmann H. Implementation of whole genome sequencing for tuberculosis diagnostics in a low-middle income, high MDR-TB burden country. Sci Rep 2021;11:15333. [PMID: 34321545 DOI: 10.1038/s41598-021-94297-z] [Reference Citation Analysis]
22 Sudharshan S, Nair N, Curi A, Banker A, Kempen JH. Human immunodeficiency virus and intraocular inflammation in the era of highly active anti retroviral therapy - An update. Indian J Ophthalmol 2020;68:1787-98. [PMID: 32823395 DOI: 10.4103/ijo.IJO_1248_20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
23 Enane LA, Christenson JC. Global emerging resistance in pediatric infections with TB, HIV, and gram-negative pathogens. Paediatr Int Child Health 2021;41:65-75. [PMID: 33305992 DOI: 10.1080/20469047.2020.1853350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Khan N, Das A. Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular? Precision Clinical Medicine 2020;3:240-3. [DOI: 10.1093/pcmedi/pbaa021] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Huynh J, Donovan J, Phu NH, Nghia HDT, Thuong NTT, Thwaites GE. Tuberculous meningitis: progress and remaining questions. The Lancet Neurology 2022;21:450-64. [DOI: 10.1016/s1474-4422(21)00435-x] [Reference Citation Analysis]
26 Woldeyohannes D, Tekalegn Y, Sahiledengle B, Assefa T, Aman R, Hailemariam Z, Mwanri L, Girma A. Predictors of mortality and loss to follow-up among drug resistant tuberculosis patients in Oromia Hospitals, Ethiopia: A retrospective follow-up study. PLoS One 2021;16:e0250804. [PMID: 33956812 DOI: 10.1371/journal.pone.0250804] [Reference Citation Analysis]
27 Alghamdi WA, Al-Shaer MH, Kipiani M, Barbakadze K, Mikiashvili L, Kempker RR, Peloquin CA. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis. J Antimicrob Chemother 2021;76:1019-24. [PMID: 33378452 DOI: 10.1093/jac/dkaa550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Dubois M, Dixit A, Lamb G. Tuberculosis in Pediatric Solid Organ and Hematopoietic Stem Cell Recipients. Glob Pediatr Health 2021;8:2333794X20981548. [PMID: 33506075 DOI: 10.1177/2333794X20981548] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Nolt D, Starke JR. Tuberculosis Infection in Children and Adolescents: Testing and Treatment. Pediatrics 2021;148:e2021054663. [PMID: 34851422 DOI: 10.1542/peds.2021-054663] [Reference Citation Analysis]
30 Shiu JR, Min A, Kiang TKL. Clinical Pharmacokinetics and Pharmacodynamics of Anti-Tubercular Drugs in Pregnancy. Eur J Drug Metab Pharmacokinet 2021;46:1-24. [PMID: 33206364 DOI: 10.1007/s13318-020-00657-x] [Reference Citation Analysis]
31 Xu Y, Wang G, Xu M. Biohazard levels and biosafety protection for Mycobacterium tuberculosis strains with different virulence. Biosafety and Health 2020;2:135-41. [DOI: 10.1016/j.bsheal.2020.04.001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Krug S, Parveen S, Bishai WR. Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis. Front Immunol 2021;12:660916. [PMID: 33953722 DOI: 10.3389/fimmu.2021.660916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Katrak S, Lowenthal P, Shen R, True L, Henry L, Barry P. Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. J Clin Tuberc Other Mycobact Dis 2021;23:100216. [PMID: 33598568 DOI: 10.1016/j.jctube.2021.100216] [Reference Citation Analysis]
34 D'Ambrosio L, Centis R, Dobler CC, Tiberi S, Matteelli A, Denholm J, Zenner D, Al-Abri S, Alyaquobi F, Arbex MA, Belilovskiy E, Blanc FX, Borisov S, Carvalho ACC, Chakaya JM, Cocco N, Codecasa LR, Dalcolmo MP, Dheda K, Dinh-Xuan AT, Esposito SR, García-García JM, Li Y, Manga S, Marchese V, Muñoz Torrico M, Pontali E, Rendon A, Rossato Silva D, Singla R, Solovic I, Sotgiu G, van den Boom M, Nhung NV, Zellweger JP, Migliori GB. Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. Antibiotics (Basel) 2021;10:1355. [PMID: 34827293 DOI: 10.3390/antibiotics10111355] [Reference Citation Analysis]
35 Ghimire S, Karki S, Maharjan B, Kosterink JGW, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JW. Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study. BMJ Open Respir Res 2020;7:e000606. [PMID: 32796020 DOI: 10.1136/bmjresp-2020-000606] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Edwards BD, Edwards J, Cooper R, Kunimoto D, Somayaji R, Fisher D. Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017. PLoS One 2020;15:e0229691. [PMID: 32155169 DOI: 10.1371/journal.pone.0229691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Abulfathi AA, Donald PR, Adams K, Svensson EM, Diacon AH, Reuter H. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance. Br J Clin Pharmacol 2020;86:2123-32. [PMID: 32470182 DOI: 10.1111/bcp.14395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 de Oliveira Santos JV, da Costa Júnior SD, de Fátima Ramos Dos Santos Medeiros SM, Cavalcanti IDL, de Souza JB, Coriolano DL, da Silva WRC, Alves MHME, Cavalcanti IMF. Panorama of Bacterial Infections Caused by Epidemic Resistant Strains. Curr Microbiol 2022;79:175. [PMID: 35488983 DOI: 10.1007/s00284-022-02875-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Kim HY, Srivastava S, Ak HK, Marais BJ, Alffenaar JW. Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment. Antimicrob Agents Chemother 2020;64:e00287-20. [PMID: 32366715 DOI: 10.1128/AAC.00287-20] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Wasserman S, Furin J. Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations. Am J Respir Crit Care Med 2020;201:1331-3. [PMID: 32078783 DOI: 10.1164/rccm.202002-0264ED] [Reference Citation Analysis]
41 Pecora F, Dal Canto G, Veronese P, Esposito S. Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid. Microorganisms 2021;9:1074. [PMID: 34067732 DOI: 10.3390/microorganisms9051074] [Reference Citation Analysis]
42 Gould AP, Winders HR, Stover KR, Bookstaver PB, Griffin B, Bland CM, Eiland LS, Murray M. Less common bacterial, fungal and viral infections: review of management in the pregnant patient. Drugs Context 2021;10:2021-4-3. [PMID: 34603460 DOI: 10.7573/dic.2021-4-3] [Reference Citation Analysis]
43 Mohamed S, Mvungi HC, Sariko M, Rao P, Mbelele P, Jongedijk EM, van Winkel CAJ, Touw DJ, Stroup S, Alffenaar JC, Mpagama S, Heysell SK. Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. J Antimicrob Chemother 2021;76:1547-52. [PMID: 33675664 DOI: 10.1093/jac/dkab057] [Reference Citation Analysis]
44 Fornasaro S, Cialla-may D, Sergo V, Bonifacio A. The Role of Surface Enhanced Raman Scattering for Therapeutic Drug Monitoring of Antimicrobial Agents. Chemosensors 2022;10:128. [DOI: 10.3390/chemosensors10040128] [Reference Citation Analysis]
45 Ong CC, Teo LL. Endemic Thoracic Infections in Southeast Asia. Radiologic Clinics of North America 2022;60:445-59. [DOI: 10.1016/j.rcl.2022.01.002] [Reference Citation Analysis]
46 Bonnet I, Enouf V, Morel F, Ok V, Jaffré J, Jarlier V, Aubry A, Robert J, Sougakoff W. A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Front Cell Infect Microbiol 2021;11:707244. [PMID: 34778100 DOI: 10.3389/fcimb.2021.707244] [Reference Citation Analysis]
47 Silva DR, Mello FCQ, Migliori GB. Shortened tuberculosis treatment regimens: what is new? J Bras Pneumol 2020;46:e20200009. [PMID: 32215450 DOI: 10.36416/1806-3756/e20200009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Koh EI, Oluoch PO, Ruecker N, Proulx MK, Soni V, Murphy KC, Papavinasasundaram K, Reames CJ, Trujillo C, Zaveri A, Zimmerman MD, Aslebagh R, Baker RE, Shaffer SA, Guinn KM, Fitzgerald M, Dartois V, Ehrt S, Hung DT, Ioerger TR, Rubin EJ, Rhee KY, Schnappinger D, Sassetti CM. Chemical-genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy. Proc Natl Acad Sci U S A 2022;119:e2201632119. [PMID: 35380903 DOI: 10.1073/pnas.2201632119] [Reference Citation Analysis]
49 Thakur C, Tripathi A, Ravichandran S, Shivananjaiah A, Chakraborty A, Varadappa S, Chikkavenkatappa N, Nagarajan D, Lakshminarasimhaiah S, Singh A, Chandra N. A new blood-based RNA signature (R9), for monitoring effectiveness of tuberculosis treatment in a South Indian longitudinal cohort. iScience 2022;25:103745. [DOI: 10.1016/j.isci.2022.103745] [Reference Citation Analysis]
50 Sturkenboom MGG, Märtson AG, Svensson EM, Sloan DJ, Dooley KE, van den Elsen SHJ, Denti P, Peloquin CA, Aarnoutse RE, Alffenaar JC. Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clin Pharmacokinet 2021;60:685-710. [PMID: 33674941 DOI: 10.1007/s40262-021-00997-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Srivastava S, Gumbo T, Thomas T. Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis. Front Pharmacol 2021;12:776969. [PMID: 34744753 DOI: 10.3389/fphar.2021.776969] [Reference Citation Analysis]
52 Cole B, Nilsen DM, Will L, Etkind SC, Burgos M, Chorba T. Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association. MMWR Recomm Rep 2020;69:1-27. [PMID: 32730235 DOI: 10.15585/mmwr.rr6907a1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Gill CM, Dolan L, Piggott LM, Mclaughlin AM. New developments in tuberculosis diagnosis and treatment. Breathe 2022;18:210149. [DOI: 10.1183/20734735.0149-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Eddy JJ, Gadani KM, Tibbs A, Bernardo J, Cochran J, White LF, Horsburgh CR Jr, Jacobson KR. Increasing Drug Resistance Among Persons With Tuberculosis in Massachusetts, 2009-2018. Open Forum Infect Dis 2020;7:ofaa300. [PMID: 32855987 DOI: 10.1093/ofid/ofaa300] [Reference Citation Analysis]
55 Mirzayev F, Viney K, Linh NN, Gonzalez-Angulo L, Gegia M, Jaramillo E, Zignol M, Kasaeva T. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J 2021;57:2003300. [PMID: 33243847 DOI: 10.1183/13993003.03300-2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
56 Edwards BD, Edwards J, Cooper R, Kunimoto D, Somayaji R, Fisher D. Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting. PLoS One 2021;16:e0246993. [PMID: 33592031 DOI: 10.1371/journal.pone.0246993] [Reference Citation Analysis]
57 . Erratum: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201:500-1. [PMID: 32057258 DOI: 10.1164/rccm.v201erratum2] [Reference Citation Analysis]
58 Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:285-9. [PMID: 35202353 DOI: 10.15585/mmwr.mm7108a1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Rodríguez-García Á, Mares-Alejandre RE, Muñoz-Muñoz PLA, Ruvalcaba-Ruiz S, González-Sánchez RA, Bernáldez-Sarabia J, Meléndez-López SG, Licea-Navarro AF, Ramos-Ibarra MA. Molecular Analysis of Streptomycin Resistance Genes in Clinical Strains of Mycobacterium tuberculosis and Biocomputational Analysis of the MtGidB L101F Variant. Antibiotics (Basel) 2021;10:807. [PMID: 34356728 DOI: 10.3390/antibiotics10070807] [Reference Citation Analysis]
60 Kashongwe IM, Mawete F, Mbulula L, Nsuela DJ, Losenga L, Anshambi N, Aloni M, Kaswa M, Kayembe JMN, Umba P, Lepira FB, Kashongwe ZM. Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: A retrospective cohort study. PLoS One 2020;15:e0236264. [PMID: 32750060 DOI: 10.1371/journal.pone.0236264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Qiao J, Cheng C, Feng J, Dai X, Xu F, Xia P. Analysis of efficacy and safety of linezolid-based chemotherapeutic regimens for postoperative multidrug-resistant spinal tuberculosis patients. Int J Infect Dis 2022:S1201-9712(22)00159-X. [PMID: 35339715 DOI: 10.1016/j.ijid.2022.03.020] [Reference Citation Analysis]
62 Howell P, Achar J, Huang GKL, Mariandyshev A, Schaaf HS, Garcia-Prats AJ. Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities. Pathogens 2022;11:381. [PMID: 35456056 DOI: 10.3390/pathogens11040381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Abdelwahab MT, Wasserman S, Brust JCM, Gandhi NR, Meintjes G, Everitt D, Diacon A, Dawson R, Wiesner L, Svensson EM, Maartens G, Denti P. Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother 2020;75:3269-77. [PMID: 32747933 DOI: 10.1093/jac/dkaa310] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
64 Gopalaswamy R, Shanmugam S, Mondal R, Subbian S. Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci 2020;27:74. [PMID: 32552732 DOI: 10.1186/s12929-020-00667-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
65 Prasad R, Saxena H, Gupta N, Tanzeem M, Naorem R. Treatment of Drug-Resistant Tuberculosis: Current Status. Annals of the National Academy of Medical Sciences (India) 2021;57:068-73. [DOI: 10.1055/s-0040-1714201] [Reference Citation Analysis]
66 Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G; AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis 2021;21:975-83. [PMID: 33587897 DOI: 10.1016/S1473-3099(20)30770-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Florou Z, Gerogianni I, Gourgoulianis K, Petinaki E. New mutations in gidB gene associated with streptomycin resistance in Mycobacterium tuberculosis in Greece. J Glob Antimicrob Resist 2021;27:279-81. [PMID: 34742910 DOI: 10.1016/j.jgar.2021.10.008] [Reference Citation Analysis]
68 Gopalaswamy R, Dusthackeer VNA, Kannayan S, Subbian S. Extrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance. JoR 2021;1:141-64. [DOI: 10.3390/jor1020015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Ashy N, Alharbi L, Alkhamisi R, Alradadi R, Eljaaly K. Efficacy of erythromycin compared to clarithromycin and azithromycin in adults or adolescents with community-acquired pneumonia: A Systematic Review and meta-analysis of randomized controlled trials. J Infect Chemother 2022;28:1148-52. [PMID: 35523718 DOI: 10.1016/j.jiac.2022.04.020] [Reference Citation Analysis]
70 Beeler Asay GR, Lam CK, Stewart B, Mangan JM, Romo L, Marks SM, Morris SB, Gummo CL, Keh CE, Hill AN, Thomas A, Macaraig M, St John K, J Ampie T, Chuck C, Burzynski J. Cost of Tuberculosis Therapy Directly Observed on Video for Health Departments and Patients in New York City; San Francisco, California; and Rhode Island (2017-2018). Am J Public Health 2020;110:1696-703. [PMID: 32941064 DOI: 10.2105/AJPH.2020.305877] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Nguyen Y, Mcnabb KC, Farley JE, Warren N. Examining family planning and adverse pregnancy outcomes for women with active tuberculosis disease: a systematic review. BMJ Open 2022;12:e054833. [DOI: 10.1136/bmjopen-2021-054833] [Reference Citation Analysis]
72 Cheng N, Wu S, Luo X, Xu C, Lou Q, Zhu J, You L, Li B. A Comparative Study of Chest Computed Tomography Findings: 1030 Cases of Drug-Sensitive Tuberculosis versus 516 Cases of Drug-Resistant Tuberculosis. Infect Drug Resist 2021;14:1115-28. [PMID: 33776457 DOI: 10.2147/IDR.S300754] [Reference Citation Analysis]
73 Jang JG, Chung JH. Diagnosis and treatment of multidrug-resistant tuberculosis. Yeungnam Univ J Med 2020;37:277-85. [PMID: 32883054 DOI: 10.12701/yujm.2020.00626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Alghamdi WA, Al-Shaer MH, An G, Alsultan A, Kipiani M, Barbakadze K, Mikiashvili L, Ashkin D, Griffith DE, Cegielski JP, Kempker RR, Peloquin CA. Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis. Antimicrob Agents Chemother 2020;64:e01174-20. [PMID: 32778547 DOI: 10.1128/AAC.01174-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
75 Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH; A5312 Study Team. Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial. Am J Respir Crit Care Med 2020. [PMID: 31945300 DOI: 10.1164/rccm.201910-1960OC] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
76 Haley CA, Macias P, Jasuja S, Jones BA, Rowlinson MC, Jaimon R, Onderko P, Darnall E, Gomez ME, Peloquin C, Ashkin D, Goswami ND. Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States. Emerg Infect Dis 2021;27. [PMID: 33227229 DOI: 10.3201/eid2701.203766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]